EC Number   |
Expression |
Reference |
|---|
   3.4.22.38 | down |
cathepsin K expression level is decreased in all tissues at 12 h post-infection with Aeromonas hydrophila |
708535 |
| 3.4.22.38 | down |
cathepsin K levels decrease after nonsurgical treatment of periodontitis |
707295 |
| 3.4.22.38 | down |
inhibiting calcineurin or chelation of intracellular Ca2+, prevents the stimulation of CTSK expression by nuclear factor kappaB ligand |
708580 |
| 3.4.22.38 | down |
serum cathepsin K decreases gradually after alendronate treatment (17% at 3 months, 22% at 6 months and 41% at 12 months) |
709794 |
| 3.4.22.38 | down |
significantly down-regulated in intestine following Gram-negative bacteria Vibrio anguillarum immersion challenge |
753618 |
| 3.4.22.38 | down |
SM934-testosterone inhibits proliferation and metastasis ability of breast cancer cells via inhibiting the expression of cathepsin K followed by the inhibition of Bcl-xL |
753502 |
| 3.4.22.38 | down |
vasoprotective shear stress inhibits cathepsin K protein expression and activation downstream of TNFalpha stimulation via reduced NF-kappaB activation and expression. TNFalpha stimulation activates JNK/c-jun phosphorylation, but reduction of NF-kappaB protein prevents induction of cathepsin K transcription under vasoprotective shear stress conditions |
752885 |
| 3.4.22.38 | more |
ligand of receptor activator of nuclear factor-kappaB does not induce cathepsin K expression in fibroblasts |
708423 |
| 3.4.22.38 | more |
receptor activator of nuclear factor-kappaB or small GTPase Rab do not mediate cathepsin K induction |
708148 |
| 3.4.22.38 | more |
the levels of Cath K in serum of non-small cell lung cancer are comparable to those in controls |
708541 |
